Sarcoma of the Uterus

Clinical Gynecologic Oncology

Volumn , Issue , 2007, Pages 185-199

  McMeekin, D Scott ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882503728     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-032303978-9.50009-5     Document Type: Chapter

References (110)

1. DiSaia PJ, Pecorelli S. Gynecological sarcomas. Semin Surg Oncol 1995, 10:369.
2. Kempson RL, Bari W. Uterine sarcomas: Classification, diagnosis, and prognosis. Hum Pathol 1970, 1:331.
3. Kempson RL, Hendrickson MR Smooth muscle, endometrial stromal, and mixed mullerian tumors of the uterus. Mod Pathol 2000, 13:328.
4. McCluggage WG Uterine carcinosarcomas are metaplastic carcinomas. Int J Gynecol Cancer 2002, 12:687.
5. Ober WB Uterine sarcomas: Histogenesis and taxonomy. Ann N Y Acad Sci 1959, 75:568.
6. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997, 57:5379.
7. Zhe J, Ogata S, Tamura G, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Internat J Gynecol Path 2003, 22:368.
8. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004, 93:204.
9. Curtis RE, Freedman DM, Sherman ME, et al. Risk of malignant mixed müllerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004, 96:70.
10. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986, 76:399.
11. Meredith RF, Eisert DR, Kaka Z, et al. An excess of uterine sarcomas after pelvic irradiation. Cancer 1986, 58:2003.
12. Sherman ME, Devesa SS Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003, 98:176.
13. Zelmanowicz A, Hildesheim A, Sherman ME, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed müllerian tumors. Gynecol Oncol 1998, 69:253.
14. Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005, 98:274.
15. Arrastia CD, Fruchter RG, Clark MC, et al. Uterine carcinomas: Incidence and trends in management and survival. Gynecol Oncol 1997, 65:158.
16. Buchsbaum HJ, Lifshitz S, Blythe JG Prophylactic chemotherapy in stage I and II uterine sarcoma. Gynecol Oncol 1979, 8:346.
17. Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Rad Oncol Biol Phys 2004, 58:786.
18. Chauveinc L, Deniaud E, Plancher C, et al. Uterine sarcomas: The Curie Institut experience. Prognostic factors and adjuvant treatments. Gynecol Oncol 1999, 72:232.
19. Chi DS, Mychalczak B, Saigo PE, et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997, 65:493.
20. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 1987, 60:2035.
21. Connor JP, Andrews JI, Anderson B, et al. Computeed tomography in endometrial cancer. Obstet Gynecol 2000, 95:692.
22. Curtin JP, Blessing JA, Soper JT, et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 2001, 83:268.
23. DiSaia PJ, Catro JR, Rutledge FN Mixed mesodermal sarcoma of the uterus. AJR Am J Roentgenol 1973, 117:632.
24. DiSaia PJ, Morrow CP, Boronow R, et al. Endometrial sarcoma; lymphatic spread pattern. Am J Obstet Gynecol 1978, 130:104.
25. Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998, 68:8.
26. Hannigan EV, Freedman RS, Rutledge FN Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 1983, 15:56.
27. Hannigan EV, Freedman RS, Elder KW Treatment of advanced uterine sarcoma with adriamycin. Gynecol Oncol 1983, 16:101.
28. Homesley H, Filiaci V, Bitterman P, Eaton L, et al. Phase III trial of ifosfamide versus ifosfamide plus paclitaxel as first-line treatment of advanced or recurrent uterine carcinosarcoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006, 1:S31. 101 S.
29. Hornback NB, Omura G, Major FJ Observations on the use of adjuvant radiation therapy in patient with stage I and II uterine sarcoma. Int J Radiation Oncol Biol Phys 1986, 12:2127.
30. Le T, Krepart GV, Lotocki RJ, Hewood MS Malignant mixed mesodermal ovarian tumor treatment and prognosis: A 20 year experience. Gynecol Oncol 1997, 65:237.
31. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early stage uterine sarcoma. Int J Gynecol Pathol 1992, 11:75.
32. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: A Gynecologic Oncology Group study. Cancer 1993, 71:1702.
33. Marchese MJ, et al. Uterine sarcomas: A clinico-pathologic study, 1965-1981. Gynecol Oncol 1984, 18:299.
34. Muss HB, Bundy BN, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide. Cancer 1985, 55:1648.
35. Omura GA, Blessing JA, Majors F, et al. A randomized clinical trial of adjuvant Adriamycin in uterine sarcoma: A Gynecologic Oncology Group study. J Clin Oncol 1985, 3:1240.
36. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without demethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983, 52:626.
37. Peters WA, Kumar NB, Fleming WP Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 1984, 63:550.
38. Podczaski ES, Woomert CA, Stevens CW, et al. Management of malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol 1989, 32:240.
39. Resnik E, Chambers SK, Carcangiu ML, et al. A phase II study of etoposide, cisplatin and doxorubicin chemotherapy in mixed müllerian tumors of the uterus. Gynecol Oncol 1995, 56:370.
40. Saksela E, Lampinen V, Procopé B. Malignant mesenchymal tumors of the uterine corpus. Am J Obstet Gynecol 1974, 120:452.
41. Salazar OM, Bonfiglio TA, Patten SF, et al. Uterine sarcomas: Natural history, treatment and prognosis. Cancer 1978, 42:1152.
42. Salazar OM, Bonfiglio TA, Patten SF, et al. Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 1978, 42:1161.
43. Santos A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcoma. J Clin Oncol 1995, 13:1537.
44. Sartori E, Bazzurini L, Gadducci A, et al. Carcinosarcoma of the uterus: A clinicopathological multicenter CTF study. Gynecol Oncol 1997, 67:70.
45. Spanos WJ, Peters LJ, Oswald MJ Patterns of recurrence in malignant mixed mullerian tumor of the uterus. Cancer 1986, 57:155.
46. Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1989, 12:161.
47. Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 2000, 79:147.
48. Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991, 9:1962.
49. Thigpen JT, Blessing JA, Orr JW, et al. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group study. Cancer Treat Rep 1986, 70:271.
50. Van Rijswijk REN, Tognon G, Burger CW, et al. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. Int J Gynecol Cancer 1994, 4:52.
51. Wheelock JB, Krebs HB, Schneider V, et al. Uterine sarcoma: analysis of prognostic variables in 71 cases. Am J Obstet Gynecol 1985, 151:1016.
52. Wolfson AH, Wolfson DJ, Sittler SY, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994, 52:56.
53. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: A comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol 1995, 14:134.
54. Bell SW, Kempson RL, Hendrickson MR Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994, 18:535.
55. Berchuck A, Rubin SC, Hoskins WJ Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988, 71:845.
56. Blom R, Guerrieri C, Stal O, et al. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998, 68:54.
57. Burns B, Curry RH, Bell ME Morphologic features of prognostic significance in uterine smooth muscle tumors: A review of 84 cases. Am J Obstet Gynecol 1979, 135:109.
58. Cadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: Analysis of treatment failures and survival. Gynecol Oncol 1996, 62:25.
59. Christopherson WM, Williamson EO, Gray LA Leiomyosarcomas of the uterus. Cancer 1972, 29:1512.
60. Clement PB Intravenous leiomyomatosis of the uterus. Pathol Annu 1988, 2:153.
61. Corscaden JA, Singh BP Leiomyosarcoma of the uterus. Am J Obstet Gynecol 1959, 77:286.
62. Currie JL, Blessing JA, Muss HB, et al. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996, 61:27.
63. D'Angelo A, Amso NM, Wood A. Uterine leiomyosarcoma discovered after uterine artery embolization. J Obstet Gynaecol 2003, 23:686.
64. Evans HL, Chawla SP, Simpson C, et al. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma: A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988, 62:2239.
65. Gadducci A, Landone F, Sartore E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996, 62:25.
66. Gal AA, Brooks JJ, Pietra GG Leiomyomatous neoplasms of the lung. Mod Pathol 1989, 2:209.
67. Gallup DG, Blessing JA, Anderson W, et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003, 89:48.
68. Gallup DG, Hobbs LH, Ross WB Recurrence of uterine leiomyosarcoma 25 years after therapy. Gynecol Oncol 1982, 13:293.
69. Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003, 89:460.
70. Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. Gynecol Oncol 1993, 50:105.
71. Hensley ML, Maki R, Venkatranab E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002, 20:2824.
72. Leibsohn S, d'Ablaing G, Mishell DR, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990, 76:162.
73. Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992, 45:202.
74. Lissoni A, Cormio G, Bonazzi C, et al. Fertility-sparing surgery in uterine leiomyosarcoma. Gynecol Oncol 1998, 70:348.
75. Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999, 74:196.
76. Meyer WR, Mayer AR, Diamond MP, et al. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990, 75:529.
77. Nordal RN, Kjorstad KE, Stenweg AE, Tropé CE Leiomyosarcoma and endometrial stromal sarcoma of the uterus. Int J Gynecol Cancer 1993, 3:110.
78. O'Connor DM, Norris HJ Mitotically active leiomyomas of the uterus. Hum Pathol 1990, 21:223.
79. Oliva E, Young RH, Clement PB, et al. Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol 1995, 19:757.
80. Parker WH, Fu YS, Berek JS Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994, 83:414.
81. Peters WA, Howard DR, Anderson WA, Figge DC Uterine smooth muscle tumor of uncertain malignant potential. Obstet Gynecol 1994, 83:1015.
82. Rose PG, Blessing JA, Soper JT, et al. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1998, 70:267.
83. Schwartz LB, Diamond MP, Schwartz PE Leiomyosarcomas: Clinical presentation. Am J Obstet Gynecol 1993, 180-3:168.
84. Silverberg SG Leiomyosarcoma of the uterus. Obstet Gynecol 1971, 38:613.
85. Sutton G, Blessing JA, Ball H, et al. Phase II Trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1999, 74:346.
86. Sutton G, Blessing JA, Malfetano JH, et al. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996, 62:226.
87. Sutton G, Blessing J, McGuire W, et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus. Gynecol Oncol 1990, 36:295.
88. Taylor HB, Norris HJ Mesenchymal tumors of the uterus. IV: Diagnosis and prognosis of leiomyosarcomas. Arch Pathol 1966, 82:40.
89. Thigpen JT, Blessing JA, Wilbanks GD Cisplatin as second line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. Am J Clin Oncol 1986, 9:18.
90. Thigpen T, Blessing JA, Yordan E, et al. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996, 63:120.
91. Vardi JR, Tovel HM Leiomyosarcoma of the uterus: Clinico-pathologic study. Obstet Gynecol 1980, 56:428.
92. Bohr L, Thomsen CF Low-grade stromal sarcoma: A benign appearing malignant uterine tumour; a review of current literature. Differential diagnostic problems illustrated by four cases. Eur J Obstet Gynecol Reprod Biol 1991, 39:63.
93. Chang KL, Crabtree GS, Lim-Tan SK, et al. Primary uterine endometrial stromal neoplasms: a clinicopathologic study of 117 cases. Am J Surg Pathol 1990, 14:415.
94. DiSaia PJ, Morrow CP, Boronow R, et al. Endometrial sarcoma: lymphatic spread pattern. Am J Obstet Gynecol 1978, 130:104.
95. DeFusio PA, Gaffey TA, Malkasian GD, et al. Endometrial stromal sarcomas: Review of Mayo Clinic experience, 1945-1980. Gynecol Oncol 1989, 35:8.
96. Evans HL Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 1982, 50:2170.
97. Gadducci A, Sartori E, Landoni F, et al. Endometrial stromal sarcoma: Analysis of treatment failures and survival. Gynecol Oncol 1996, 63:247.
98. Lehrner LM, Miles PA, Enck RE Complete remission of widely metastatic endometrial stromal sarcoma following combination chemotherapy. Cancer 1979, 43:1189.
99. Lin YC, Kudelka AP, Tresukosol D, et al. Case report: Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy. Gynecol Oncol 1995, 58:262.
100. Lissoni A, Cormio G, Perego P, et al. Conservative management of endometrial stromal sarcoma in young women. Int J Gynecol Oncol 1997, 7:364.
101. Nordal RR, Kristensen GB, Kaeren J, et al. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996, 62:254.
102. Norris HF, Taylor HB Mesenchymal tumors of the uterus. I: A clinical and pathological study of 53 endometrial stromal tumors. Cancer 1966, 19:755.
103. Piver MS, Rutledge FN, Copeland L, et al. Uterine endolymphatic stromal myosis: A collaborative study. Obstet Gynecol 1984, 64:173.
104. Scribner DR, Walker JL Case report: Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Gynecol Oncol 1998, 71:458.
105. Clement PB Müllerian adenosarcoma of the uterus with sarcomatous overgrowth: A clinicopathological analysis of 10 cases. Am J Surg Pathol 1989, 13:28.
106. Clement PB, Scully RE Müllerian adenosarcoma of the uterus: A clinical pathological analysis of 100 cases with review of the literature. Hum Pathol 1990, 21:363.
107. Hammerman RM, Runowicz CD Conservative management of uterine rhabdomyosarcoma. Obstet Gynecol 1998, 92:669.
108. Kaku T, Silverberg SG, Blessing J, et al. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol 1992, 11:75.
109. Krivac TC, Seidman JD, McBroom JW, et al. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 2001, 83:89.
110. Zaloudek CJ, Norris HJ Adenofibroma and adenosarcoma of the uterus: A clinicopathologic study of 35 cases. Cancer 1981, 48:354.